Skip to main content

Morphing brain DNA hints at a whole new way to treat Alzheimer’s

Morphing brain DNA hints at a whole new way to treat Alzheimer’s:

Amyloid protein in Alzheimer's disease.
People with Alzheimer’s disease get a build up of a protein in the brain called beta-amyloid.

 By Alice Klein

Brain cells are reshuffling their own DNA. The finding may explain how Alzheimer’s disease develops and pave the way for new treatments using existing HIV drugs.
Most drugs for treating Alzheimer’s disease are designed to clear out clumps of beta-amyloid protein that build up in the brain of people with the condition. But they have had disappointing outcomes in clinical trials so far.
While studying the gene responsible for making beta-amyloid – called APP – Jerold Chun at Sanford Burnham Prebys Medical Discovery Institute in California and his colleagues discovered something strange. The gene appeared to be able to reshuffle its DNA, allowing it to take thousands of different forms.
The team found about 10 times more variants of the APP gene in brain cells from people with Alzheimer’s disease than without. These different forms were able to produce a range of toxic proteins in addition to beta-amyloid.
The finding may explain why Alzheimer’s drugs that specifically target beta-amyloid have had limited success, says Chun. “They may be missing thousands of other toxic products that are a bit different or maybe very different,” he says.

Shapeshifting gene

At the moment, it’s unclear why the APP gene is able to morph into different forms. In healthy people, it may give the brain greater flexibility by letting it produce a wider repertoire of signaling proteins, says Chun.
We also don’t know why the gene seems to shapeshift more in the brains of people with Alzheimer’s disease, says Chun. So far, his team’s research suggests that it is linked to the activity of a group of enzymes called reverse transcriptases.
The same enzymes are already well-known in the context of HIV, as they are responsible for letting the virus insert itself in infected people’s DNA. It’s possible that existing HIV drugs that block these enzymes  – called reverse transcriptase inhibitors – may also be useful for treating Alzheimer’s disease, says Chun.
This idea is supported by the observation that elderly HIV patients who have been on long-term treatment with reverse transcriptase inhibitors seem rarely to develop Alzheimer’s disease. However, clinical trials will be needed to prove it, says Chun.
His team is currently testing the effectiveness of already-available reverse transcriptase inhibitors for HIV in mouse models of Alzheimer’s disease, as well as planning possible future trials in humans. “The great thing about these drugs is that many of them have been used in HIV patients for decades, so we already know they’re safe,” he says.

Comments

Post a Comment

Popular posts from this blog

Size matters: New data reveals cell size sparks genome awakening in embryos

Transitions are a hallmark of life. When dormant plants flower in the spring or when a young adult strikes out on their own, there is a shift in control. Similarly, there is a transition during early development when an embryo undergoes biochemical changes, switching from being controlled by maternal molecules to being governed by its own genome. For the first time, a team from the Perelman School of Medicine at the University of Pennsylvania found in an embryo that activation of its genome does not happen all at once, instead it follows a specific pattern controlled primarily by the various sizes of its cells. The researchers published their results this week as the cover story in  Developmental Cell . In an early embryo undergoing cell division, maternally loaded RNA and proteins regulate the cell cycle. The genomes of the zygote -- a term for the fertilized egg -- are initially in sleep mode. However, at a point in the early life of the embryo, these zygotic nuclei "wake...
Post a Comment
Read more

Home births as safe as hospital births: International study suggests

A large international study led by McMaster University shows that low risk pregnant women who intend to give birth at home have no increased chance of the baby's perinatal or neonatal death compared to other low risk women who intend to give birth in a hospital. The results have been published by  The Lancet 's  EClinicalMedicine  journal. "More women in well-resourced countries are choosing birth at home, but concerns have persisted about their safety," said Eileen Hutton, professor emeritus of obstetrics and gynecology at McMaster, founding director of the McMaster Midwifery Research Centre and first author of the paper. "This research clearly demonstrates the risk is no different when the birth is intended to be at home or in hospital." The study examined the safety of place of birth by reporting on the risk of death at the time of birth or within the first four weeks, and found no clinically important or statistically different risk between home...
Post a Comment
Read more

Molecular adlayer produced by dissolving water-insoluble nanographene in water

Molecular adlayer produced by dissolving water-insoluble nanographene in water : "Nanographene incorporated micelle capsules" can be prepared by simply pulverizing and mixing nanographene with amphiphilic V-shaped anthracene molecules in water at room temperature. Even though nanographene is insoluble in water and organic solvents, Kumamoto University (KU) and Tokyo Institute of Technology (Tokyo Tech) researchers have found a way to dissolve it in water. Using "molecular containers" that encapsulate water-insoluble molecules, the researchers developed a formation procedure for a nanographene adlayer, a layer that chemically interacts with the underlying substance, by just mixing the molecular containers and nanographene together in water. The method is expected to be useful for the fabrication and analysis of next-generation functional nanomaterials. Graphene is a single layer of carbon atoms arranged in sheet form. It is lighter than metal wit...
Post a Comment
Read more